Interesting that this talks about a completed phase II trial of an oral treatment. I hope if they do another trial it will be phase III.
Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis.
J Interferon Cytokine Res. 2006 Mar;26(3):150-5.
Brod SA, Nguyen M, Hood Z, Shipley GL.
Department of Neurology, University of Texas-Houston, Health Science Center (UTHHSC), Houston, TX 77030, USA. email@example.com
In a phase II trial ...